EGFR-activating mutations correlate with a fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity

Cancer Research

Volumn 73, Issue 20, 2013, Pages 6254-6263

  Pfaäffle, Heike N ^a,d   Wang, Meng ^a   Gheorghiu, Liliana ^a   Ferraiolo, Natalie ^a   Greninger, Patricia ^b   Borgmann, Kerstin ^e   Settleman, Jeffrey ^b,c   Benes, Cyril H ^b   Sequist, Lecia V ^a   Zou, Lee ^b   Willers, Henning ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FANCONI ANEMIA GROUP D2 PROTEIN; GAMMA HISTONE H2AX; HISTONE H2AX; MITOMYCIN; OLAPARIB; RAD51 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHROMOSOME ABERRATION; CHROMOSOME RADIAL FORMATION; CONTROLLED STUDY; DNA CROSS LINKING; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG SENSITIVITY; EGFR GENE; EMBRYO; ENZYME INHIBITION; ENZYME REGULATION; EPISTASIS; EX VIVO STUDY; FAN1 GENE; FANCD2 GENE; FANCONI ANEMIA LIKE CELLULAR PHENOTYPE; G2 PHASE CELL CYCLE CHECKPOINT; GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPLETION; RECOMBINATION REPAIR; SURVIVAL RATE; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CISPLATIN; ENZYME INHIBITORS; EXODEOXYRIBONUCLEASES; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; HUMANS; LUNG NEOPLASMS; MICE; MUTATION; NIH 3T3 CELLS; POLY(ADP-RIBOSE) POLYMERASES; RAD51 RECOMBINASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINATION, GENETIC; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84886075135     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0044     Document Type: Article

References (49)

1. Pao W, Girard N. New driver mutations in non-small cell lung cancer. Lancet Oncol 2011; 12:175-80.
2. Neal JW, Sequist LV First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. Clin Adv Hematol Oncol 2010; 8:119-26.
3. Mok TS, Wu YL, Thongprasert S, Yang C.H., Chu DT, Saijo N, et al Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-57.
4. Janne PA, Wang X, Socinski M.A., Crawford J., Stinchcombe TE, Gu L, et al Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol 2012; 30:2063-9.
5. Eberhard DA, Johnson BE, Amler L.C., Goddard AD, Heldens SL, Herbst RS, et al Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23:5900-9.
6. Das AK, Chen BP, Story M.D., Sato M., Minna JD, Chen DJ, et al Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res 2007; 67:5267-74.
7. Dittmann K, Mayer C, Fehrenbacher B., Schaller M, Raju U, Milas L., et al Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005; 280:31182-9.
8. Liccardi G, Hartley JA, Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res 2011; 71:1103-14.
9. Frankenberg-Schwager M., Kirchermeier D, Greif G., Baer K, Becker M, Frankenberg D. Cisplatin-mediated DNA double-strand breaks in replicating but not in quiescent cells of the yeast Saccharomyces cerevisiae. Toxicology 2005; 212:175-84.
10. Collins AR. Mutant rodent cell lines sensitive to ultraviolet light, ionizing radiation and cross-linking agents: a comprehensive survey of genetic and biochemical characteristics. Mutat Res 1993; 293: 99-118.
11. Willers H, Pfäaffle HN, Zou L. Targeting Homologous Recombination Repair in Cancer. In Kelley MR (ed): DNA Repair in Cancer Therapy: Molecular Targets and Clinical Applications. Waltham: Academic Press, Elsevier, 2012, pp. 119-160.
12. Kachnic LA, Li L, Fournier L., Willers H. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments. Cancer Lett 2010; 292:73-9.
13. Birkelbach M, Ferraiolo N, Gheorghiu L., Pfaäffle HN, Daly B., Ebright M, et al Detection of impaired homologous recombination repair in NSCLC cells and tissues. J Thorac Oncol 2013; 8:279-86.
14. Bhattacharyya A, Ear US, Koller B.H., Weichselbaum RR, Bishop DK The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000; 275: 23899-903.
15. Garcia-Higuera I., Taniguchi T, Ganesan S., Meyn MS, Timmers C, Hejna J, et al Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001; 7:249-62.
16. Bryant HE, Helleday T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res 2006; 34:1685-91.
17. Murai J, Huang SY, Das B.B., Renaud A., Zhang Y, Doroshow JH, et al Trapping of PARP1 and PARP2 by clinical PARPinhibitors. Cancer Res 2012; 72:5588-99.
18. Bryant HE, Schultz N, Thomas H.D., Parker KM, Flower D, Lopez E, et al Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005; 434:913-7.
19. Farmer H, McCabe N, Lord C.J., Tutt AN, Johnson DA, Richardson TB, et al Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21.
20. McCabe N, Turner NC, Lord C.J., Kluzek K., Bialkowska A, Swift S, et al Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66:8109-15.
21. Cybulski KE, Howlett NG FANCP/SLX4: a Swiss army knife of DNA interstrand crosslink repair. Cell Cycle 2011; 10:1757-63.
22. Deans AJ, West SC DNA interstrand crosslink repair and cancer. Nat Rev Cancer 2011; 11:467-80.
23. Muniandy PA, Liu J, Majumdar A., Liu ST, Seidman MM DNA interstrand crosslink repair in mammalian cells: step by step. Crit Rev Biochem Mol Biol 2010; 45:23-49.
24. Kim H, D'Andrea AD. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev 2012; 26:1393-408.
25. MacKay C, Declais AC, Lundin C, Agostinho A., Deans AJ, MacArtney TJ, et al Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. Cell 2010; 142:65-76.
26. Smogorzewska A, Desetty R, Saito T.T., Schlabach M., Lach FP, Sowa ME, et al A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol Cell 2010; 39:36-47.
27. Liu T, Ghosal G, Yuan J., Chen J, Huang J. FAN1 acts with FANCIFANCD2 to promote DNA interstrand cross-link repair. Science 2010; 329:693-6.
28. Willers H, Kachnic LA, Luo C-M, Li L, Purschke M., Borgmann K, et al Biomarkers and mechanisms of FANCD2 function. J Biomed Biotechnol 2008; 2008:821529.
29. Nakanishi K, Yang YG, Pierce A.J., Taniguchi T., Digweed M, D'Andrea AD, et al Human Fanconi anemia monoubiquitination pathway promotes homologous DNA repair. Proc Natl Acad Sci U S A 2005; 102: 1110-5.
30. Litman R, Peng M, Jin Z., Zhang F, Zhang J, Powell S., et al BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell 2005; 8:255-65.
31. Wang M, Morsbach F, Sander D., Gheorghiu L, Nanda A, Benes C., et al EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res 2011; 71:6261-9.
32. Garnett MJ, Edelman EJ, Heidorn S.J., Greenman CD, Dastur A, Lau KW, et al Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012; 483:570-5.
33. Yuza Y, Glatt KA, Jiang J, Greulich H., Minami Y, Woo MS, et al Alleledependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther 2007; 6:661-7.
34. Willers H, Taghian AG, Luo C-M, Treszezamsky AD, Sgroi D, Powell SN Utility of DNA repair protein foci for the detection of putative BRCA1-pathway defects in breast cancer biopsies. Mol Cancer Res 2009; 7:1304-9.
35. Sordella R, Bell DW, Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-7.
36. Kachnic LA, Li L, Fournier L., Ferraiolo N, Dahm-Daphi J, Borgmann K, et al FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons. Cancer Lett 2011; 305:86-93.
37. Kennedy RD, Chen CC, Stuckert P, Archila E.M., De laVega MA, Moreau LA, et al Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 2007; 117:1440-9.
38. Plo I, Laulier C, Gauthier L., Lebrun F, Calvo F, Lopez BS AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. Cancer Res 2008; 68:9404-12.
39. Yamamoto KN, Kobayashi S, Tsuda M., Kurumizaka H, Takata M, Kono K., et al Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway. Proc Natl Acad Sci U S A 2011; 108: 6492-6.
40. Long DT, Raschle M, Joukov V., Walter JC Mechanism of RAD51dependent DNA interstrand cross-link repair. Science 2011; 333: 84-7.
41. Li L, Wang H, Yang E.S., Arteaga CL, Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res 2008; 68:9141-6.
42. Myllynen L, Rieckmann T, Dahm-Daphi J, Kasten-Pisula U, Petersen C, Dikomey E., et al In tumor cells regulation of DNA double strand break repair through EGF receptor involves both NHEJ and HR and is independent of p53 and K-Ras status. Radiother Oncol 2011; 101:147-51.
43. Gandara DR, Grimminger P, Mack P.C., Lara PN Jr, Li T, Danenberg PV, et al Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol 2010; 5:1933-8.
44. Al-Minawi A.Z., Lee YF, Hakansson D, Johansson F., Lundin C, Saleh Gohari N, et al The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucleic Acids Res 2009; 37:6400-13.
45. Marks JL, Golas B, Kirchoff T., Miller VA, Riely GJ, Offit K, et al EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations. J Thorac Oncol 2008; 3:805.
46. Lakhani SR, Reis-Filho JS, Fulford L., Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11:5175-80.
47. Nitta M, Kozono D, Kennedy R., Stommel J, Ng K, Zinn P.O., et al Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PLoS ONE 2010; 5:e10767.
48. Thompson LH, Hinz JM Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mutat Res 2009; 668:54-72.
49. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319: 1352-5.